Can inflammation raise ferritin while serum iron markers stay normal?

In patients presenting with elevated ferritin—particularly in demographic groups such as postmenopausal women where metabolic and inflammatory shifts are highly prevalent—distinguishing true systemic iron overload from inflammatory sequestration is clinically vital.

Molecular mechanisms of iron sequestration

• Cytokine-driven ferritin synthesis: Pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) directly upregulate ferritin heavy chain (FTH1) gene transcription. TNF-α activates the NF-κB pathway to bind the FER-2 promoter enhancer, while IL-6 acts via the JAK-STAT3 pathway. These cytokines bypass normal iron-responsive element (IRE) translational regulation, driving rapid, iron-independent ferritin synthesis.
• Hepcidin-mediated ferroportin degradation: Concurrently, IL-6-mediated JAK-STAT3 signaling upregulates hepatic hepcidin (HAMP gene) transcription. Systemic hepcidin binds to ferroportin, the sole cellular iron exporter on macrophages and hepatocytes, triggering its ubiquitination, clathrin-mediated endocytosis, and lysosomal degradation. This abruptly halts cellular iron export, forcing intracellular sequestration.

Systemic markers and clinical presentation

• Isolated hyperferritinemia: Because iron remains trapped intracellularly, it cannot be released into the plasma. Consequently, circulating markers—such as serum iron, total iron binding capacity (TIBC), and transferrin saturation (TSAT)—remain entirely within normal reference ranges despite high intracellular storage.
• Differential diagnosis: Over 90% of isolated hyperferritinemia cases are driven by non-iron-overload etiologies like low-grade inflammation, metabolic syndrome, or fatty liver disease. While hereditary hemochromatosis typically presents with an elevated TSAT (often >45%), inflammatory sequestration is characterized by high ferritin paired with normal TSAT.

Bottom line

• Key takeaway: Elevated ferritin paired with normal serum iron, TSAT, and TIBC is a classic hallmark of inflammatory or metabolic sequestration driven by the IL-6/hepcidin/ferroportin pathway. Clinical management should focus on treating the underlying inflammatory or metabolic drivers rather than initiating therapeutic phlebotomy.